{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:10:41Z","timestamp":1769004641088,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL-70227"],"award-info":[{"award-number":["R01 HL-70227"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001277","name":"Oishei Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.xphs.2017.10.038","type":"journal-article","created":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T05:36:01Z","timestamp":1509600961000},"page":"831-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lipidic Nanoparticles Comprising Phosphatidylinositol Mitigate Immunogenicity and Improve Efficacy of Recombinant Human Acid Alpha-Glucosidase in a Murine Model of Pompe Disease"],"prefix":"10.1016","volume":"107","author":[{"given":"Jennifer L.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Dingman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathy V.","family":"Balu-Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2017.10.038_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"\u03b1-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.xphs.2017.10.038_bib2","first-page":"132","article-title":"Recombinant human acid \u03b1-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.xphs.2017.10.038_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.xphs.2017.10.038_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","article-title":"Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells","volume":"105","author":"Banugaria","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.xphs.2017.10.038_bib5","unstructured":"Myozyme [package insert]. Cambridge, MA: Genzyme Corporation; 2006"},{"issue":"1","key":"10.1016\/j.xphs.2017.10.038_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.xphs.2017.10.038_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-1-6","article-title":"Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts","volume":"1","author":"Cardone","year":"2008","journal-title":"Pathogenetics"},{"issue":"7","key":"10.1016\/j.xphs.2017.10.038_bib8","doi-asserted-by":"crossref","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid \u03b1-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.xphs.2017.10.038_bib9","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid \u03b1-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J\u00a0Biol Chem"},{"issue":"19","key":"10.1016\/j.xphs.2017.10.038_bib10","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/jnci\/81.19.1484","article-title":"Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times","volume":"81","author":"Gabizon","year":"1989","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.xphs.2017.10.038_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1208\/s12248-010-9207-z","article-title":"Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice","volume":"12","author":"Peng","year":"2010","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.xphs.2017.10.038_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jps.23963","article-title":"Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-Domain deleted factor VIII in hemophilia a mice","volume":"104","author":"Shetty","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2017.10.038_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/bdd.1880","article-title":"Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice","volume":"35","author":"Kosloski","year":"2014","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2017.10.038_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jps.22746","article-title":"Downregulation of CD40 signal and induction of TGF-\u03b2 by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII","volume":"101","author":"Gaitonde","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2017.10.038_bib15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J\u00a0Biol Chem"},{"issue":"30","key":"10.1016\/j.xphs.2017.10.038_bib16","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid \u03b1-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xphs.2017.10.038_bib17","unstructured":"GAAtm1Rabn Standard PCR. Version 3.0. Bar Harbor, ME: The Jackson Laboratory; 2009. Available at: https:\/\/www2.jax.org\/protocolsdb\/f?p=116:5:0::NO:5:P5_MASTER_PROTOCOL_ID,P5_JRS_CODE:3742,004154. Accessed November 14, 2017."},{"issue":"1","key":"10.1016\/j.xphs.2017.10.038_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2017.10.038_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A\u00a0statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J\u00a0Immunol Methods"},{"issue":"7","key":"10.1016\/j.xphs.2017.10.038_bib20","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/jps.23566","article-title":"Allometry of factor VIII and informed scaling of next-generation therapeutic proteins","volume":"102","author":"Kosloski","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2017.10.038_bib21","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/jps.20099","article-title":"Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles","volume":"93","author":"Wajima","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2017.10.038_bib22","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1016\/j.xphs.2016.06.018","article-title":"Phosphatidylserine converts immunogenic recombinant human acid alpha-glucosidase to a tolerogenic form in a mouse model of pompe disease","volume":"105","author":"Schneider","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2017.10.038_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"9","key":"10.1016\/j.xphs.2017.10.038_bib24","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"issue":"24","key":"10.1016\/j.xphs.2017.10.038_bib25","doi-asserted-by":"crossref","first-page":"17051","DOI":"10.1074\/jbc.C112.396325","article-title":"Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice","volume":"288","author":"Gaitonde","year":"2013","journal-title":"J\u00a0Biol Chem"},{"issue":"18","key":"10.1016\/j.xphs.2017.10.038_bib26","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1073\/pnas.85.18.6949","article-title":"Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors","volume":"85","author":"Gabizon","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.xphs.2017.10.038_bib27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0014-4827(84)90779-1","article-title":"Uptake and stability of human and bovine acid \u03b1-glucosidase in cultured fibroblasts and skeletal muscle cells from glycogenosis type II patients","volume":"155","author":"Reuser","year":"1984","journal-title":"Exp Cell Res"},{"issue":"6","key":"10.1016\/j.xphs.2017.10.038_bib28","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid \u03b1-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917307773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917307773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T03:43:26Z","timestamp":1659757406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354917307773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0022354917307773"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2017.10.038","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipidic Nanoparticles Comprising Phosphatidylinositol Mitigate Immunogenicity and Improve Efficacy of Recombinant Human Acid Alpha-Glucosidase in a Murine Model of Pompe Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2017.10.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}